Samsung Bioepis Reports the EC’s approval of Obodence & Xbryk (Biosimilar, Denosumab)
Shots:
- The EC has approved SB16: Obodence (60mg pre-filled syringe; Biosimilar: Prolia) & Xbryk (120mg vial; Biosimilar: Xgeva) for osteoporosis & prevention of skeletal related events, respectively
- Approval was based on the P-I trial which confirmed PK equivalence between SB16, EU-DEN & US-DEN among healthy males (n=168), in terms of AUC from time zero to infinity & maximum serum concentration (1EPs)
- Additionally, P-III trial depicted SB16’s similar efficacy, safety, immunogenicity & PK/PD vs reference in postmenopausal osteoporosis (PMO) pts (n=457). The 1EPs of % change in lumbar spine BMD at mos.12 was met, with sustained comparability up to 18mos., incl. after switching from denosumab to SB16
Ref: Samsung Bioepis | Image: Samsung Bioepis
Related News:- Samsung Bioepis and Teva Partners to Commercialize Epysqli (Biosimilar, Soliris) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
